Molecule News and Research

RSS

Researchers unlock complex cellular mechanics that instruct glial progenitor cells to divide

In a new study appearing this month in the Journal of Neuroscience, researchers have unlocked the complex cellular mechanics that instruct specific brain cells to continue to divide. This discovery overcomes a significant technical hurdle to potential human stem cell therapies; ensuring that an abundant supply of cells is available to study and ultimately treat people with diseases.

2 Nov 2012

MH6 vaccine shows promise in treating meth addiction

Scientists at The Scripps Research Institute (TSRI) have performed successful tests of an experimental methamphetamine vaccine on rats. Vaccinated animals that received the drug were largely protected from typical signs of meth intoxication.

2 Nov 2012

TransTech Pharma to complete TTP054 Phase 2 trial on type 2 diabetes

TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013. The 90-day proof of concept study is being conducted in type 2 diabetics not well controlled with approved oral anti-diabetic agents.

2 Nov 2012

NJH researchers discover novel target for treatment of food allergies

Researchers at National Jewish Health have discovered a novel target for the treatment of food allergies. Erwin Gelfand, MD, and his colleagues report in the October 2012 issue of the Journal of Allergy and Clinical Immunology that levels of the enzyme Pim 1 kinase rise in the small intestines of peanut-allergic mice. Inhibiting activity of Pim 1 markedly reduced the allergic response to peanuts.

2 Nov 2012

Blocking hyaluronidase activity can help repair brain damage associated with MS

Researchers at Oregon Health & Science University have discovered that blocking a certain enzyme in the brain can help repair the brain damage associated with multiple sclerosis and a range of other neurological disorders.

1 Nov 2012

CSHL scientists discover new way to specifically target and kill cancer cells

Cancer cells grow fast. That's an essential characteristic of what makes them cancer cells. They've crashed through all the cell-cycle checkpoints and are continuously growing and dividing, far outstripping our normal cells. To do this they need to speed up their metabolism.

1 Nov 2012

Single dose of etanercept can improve chronic neurological dysfunction from stroke or TBI

A new ground-breaking study about to be published in the Adis journal CNS Drugs provides clinical evidence that, for the first time, chronic neurological dysfunction from stroke or traumatic brain injury can rapidly improve following a single dose of a drug that targets brain inflammation, even years after the stroke or traumatic event.

1 Nov 2012

Scientists discover first selective inhibitors of DAGL enzymes

Scientists at The Scripps Research Institute (TSRI) have discovered the first selective inhibitors of an important set of enzymes. The new inhibitors, and chemical probes based on them, now can be used to study the functions of enzymes known as diacylglycerol lipases (DAGL), their products, and the pathways they regulate.

1 Nov 2012

Ceramide might play a leading role in muscle deterioration in older adults

As men and women age, increasing quantities of fat tissue inevitably take up residence in skeletal muscle. A small study of older and younger men conducted at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University suggests that a build-up of a fat molecule known as ceramide might play a leading role in muscle deterioration in older adults.

1 Nov 2012

Isis announces preliminary data from ISIS-STAT3 Phase 1 study on cancer

Isis Pharmaceuticals, Inc. announced that preliminary data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the Oligonucleotide Therapeutics Society in Boston.

1 Nov 2012

Pins made of single atoms to fight cancer

Answers are often elusive in the fight against cancer, and Rice University chemist Zachary Ball is hoping to pin one down -- with pins made of single atoms. The work, which aims to create a drug that's effective against an "undruggable" protein, is one of the first 50 proposals funded under the National Cancer Institute's (NCI) Provocative Questions Project.

31 Oct 2012

Top-line results from Neuraltus’ NP001 Phase 2 study on amyotrophic lateral sclerosis

Neuraltus Pharmaceuticals, a private biopharmaceutical company developing novel therapies for rare neurological disorders, announced today top-line results from the Company's Phase 2 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).

30 Oct 2012

Sprint Bioscience, TPP partner to develop small molecule inhibitors of choline kinase for cancer

TPP Global Development Ltd (TPP) enters into a collaboration with Sprint Bioscience AB to develop small molecule inhibitors of choline kinase as human therapeutics for the treatment of cancer.

30 Oct 2012

Study identifies new prognostic biomarker and therapeutic target for adult B-ALL

New insight into the aggressive behavior of certain adult B-acute lymphoblastic leukemias has provided researchers with a potential new prognostic biomarker and a promising new therapeutic target.

30 Oct 2012

TTP488 slows cognitive decline in patients with mild to moderate Alzheimer's

A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer's disease.

30 Oct 2012

Scientists discover β2-syntrophin protein as new prognosis marker for prostate cancer

Scientists have discovered a molecular 'tell' in laboratory experiments that could help doctors determine the severity of a patient's prostate cancer.

30 Oct 2012

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD.

29 Oct 2012

Molecule News and Research

Researchers unlock complex cellular mechanics that instruct glial progenitor cells to divide

MH6 vaccine shows promise in treating meth addiction

TransTech Pharma to complete TTP054 Phase 2 trial on type 2 diabetes

NJH researchers discover novel target for treatment of food allergies

Blocking hyaluronidase activity can help repair brain damage associated with MS

CSHL scientists discover new way to specifically target and kill cancer cells

Single dose of etanercept can improve chronic neurological dysfunction from stroke or TBI

Scientists discover first selective inhibitors of DAGL enzymes

Ceramide might play a leading role in muscle deterioration in older adults

Isis announces preliminary data from ISIS-STAT3 Phase 1 study on cancer

Pins made of single atoms to fight cancer

Top-line results from Neuraltus’ NP001 Phase 2 study on amyotrophic lateral sclerosis

Sprint Bioscience, TPP partner to develop small molecule inhibitors of choline kinase for cancer

Study identifies new prognostic biomarker and therapeutic target for adult B-ALL

TTP488 slows cognitive decline in patients with mild to moderate Alzheimer's

Scientists discover β2-syntrophin protein as new prognosis marker for prostate cancer

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

Researchers learn how E2-79 molecule destroys complexes that induce allergic responses

New therapy to treat rare form of cystic fibrosis works in unconventional way, scientists say

Researchers use baker's yeast to identify new therapies for Lou Gehrig's disease

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News